Cargando…

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

INTRODUCTION: Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in cerebrospinal fluid (CSF) and plasma in subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yilmaz, Aylin, Gisslén, Magnus, Spudich, Serena, Lee, Evelyn, Jayewardene, Anura, Aweeka, Francesca, Price, Richard W.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731205/ https://www.ncbi.nlm.nih.gov/pubmed/19721718 http://dx.doi.org/10.1371/journal.pone.0006877

Ejemplares similares

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
por: Yilmaz, Aylin, et al.
Publicado: (2013)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
por: Hagberg, Lars, et al.
Publicado: (2010)

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection
por: Peterson, Julia, et al.
Publicado: (2014)

Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection
por: Price, Richard W., et al.
Publicado: (2013)

CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2018)

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study
por: Yilmaz, Aylin, et al.
Publicado: (2006)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study
por: Ho, Emily L, et al.
Publicado: (2011)

Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected Subjects
por: Ho, Emily L., et al.
Publicado: (2013)

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2005)

Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression
por: Gisslen, Magnus, et al.
Publicado: (2021)

Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment
por: Spudich, Serena S, et al.
Publicado: (2005)

The cerebrospinal fluid proteome in HIV infection: change associated with disease severity
por: Angel, Thomas E, et al.
Publicado: (2012)

Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection
por: Gega, Arjet, et al.
Publicado: (2015)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid – the Gothenburg HIV CSF Study Cohort
por: Hagberg, Lars, et al.
Publicado: (2023)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
por: Gisslén, Magnus, et al.
Publicado: (2012)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study
por: Ulfhammer, Gustaf, et al.
Publicado: (2021)

A Modified Method for Determination of Lumefantrine in Human Plasma by HPLC-UV and Combination of Protein Precipitation and Solid-Phase Extraction: Application to a Pharmacokinetic Study
por: Huang, Liusheng, et al.
Publicado: (2010)

Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]
por: Gisslén, Magnus, et al.
Publicado: (2016)

Cerebrospinal Fluid Viral Load and Intrathecal Immune Activation in Individuals Infected with Different HIV-1 Genetic Subtypes
por: Abdulle, Sahra, et al.
Publicado: (2008)

Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection
por: Suh, Joome, et al.
Publicado: (2014)

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia – case report
por: Andersson, Lars-Magnus, et al.
Publicado: (2006)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation
por: Cheng, Da, et al.
Publicado: (2022)

Genetic and Non-Genetic Determinants of Raltegravir Penetration into Cerebrospinal Fluid: A Single Arm Pharmacokinetic Study
por: Johnson, Daniel H., et al.
Publicado: (2013)

Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection
por: Anesten, Birgitta, et al.
Publicado: (2021)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Correction: Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection
por: Anesten, Birgitta, et al.
Publicado: (2022)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1
por: Peluso, Michael J, et al.
Publicado: (2020)

Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection
por: Sharma, Vishakha, et al.
Publicado: (2021)

Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV
por: Anesten, Birgitta, et al.
Publicado: (2016)

Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study
por: Alagaratnam, Jasmini, et al.
Publicado: (2021)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
por: Edén, Arvid, et al.
Publicado: (2022)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0ofrk9v764lkdf5aadrfr99l8c